[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:burkitt-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":223,"states":248},"Burkitt Lymphoma",35,30,[8,16,23,29,35,41,48,54,60,66,72,78,84,90,96,102,108,114,120,126,132,138,144,150,156,162,167,173,179,185,190,197,203,210,217],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07069699","Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:16:54.876240Z","2026-05-05T02:43:27.175695Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05389423","Pomalidomide and Dose-Adjusted EPOCH +\u002F- Rituximab for HIV-Associated Lymphomas",[20],"Phase 1","2026-08-26T02:19:23.493898Z","2026-05-05T02:35:31.746900Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT05442515","CD19\u002FCD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies",[12],"2026-08-26T02:18:21.216897Z","2026-07-05T05:32:16.802455Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT04545762","Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma",[20],"2026-08-26T02:18:03.638950Z","2026-07-05T03:45:20.448716Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05470491","Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...",[12],"2026-08-26T02:17:35.666428Z","2026-05-05T02:43:29.587324Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT05260957","CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory\u002FRelapsed Aggressive Non-Hodgkin's Lymphoma (NHL).",[45],"Phase 2","2026-08-26T02:18:59.761994Z","2026-05-05T02:43:29.501361Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT03223610","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed\u002FRefractory B-cell Lymphoma",[12],"2026-08-26T02:17:15.156099Z","2026-05-05T02:43:29.367349Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05794880","MCW Alpha\u002FBeta T-Cell and B-Cell Depletion With Targeted ATG Dosing",[],"2026-08-26T02:18:43.501109Z","2026-05-05T02:43:29.363482Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT03810196","CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ\u002FCD19 Depleted HSCT",[],"2026-08-26T02:16:54.044282Z","2026-05-05T02:43:29.362818Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT05544019","Study of SGR-1505 in Mature B-Cell Neoplasms",[20],"2026-08-26T02:15:49.658025Z","2026-05-05T02:43:28.973931Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT04223765","Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed\u002FRefractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia\u002FSmall Lymphocytic Lymphoma.",[20],"2026-08-26T02:19:12.219640Z","2026-05-05T02:43:28.733566Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT04329728","The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies",[12],"2026-08-26T02:15:48.613507Z","2026-05-05T02:43:28.628795Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT04491370","Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma",[12],"2026-08-26T02:17:50.500039Z","2026-05-05T02:43:28.622855Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT03136146","Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma\u002FLeukemia, or Double-Hit Lymphoma\u002FLeukemia",[45],"2026-08-26T02:18:35.425468Z","2026-05-05T02:43:28.565200Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT02393157","Obinutuzumab and ICE Chemotherapy in Refractory\u002FRecurrent CD20+ Mature NHL",[45],"2026-08-26T02:17:44.240289Z","2026-05-05T02:43:28.289405Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT03314974","Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders",[45],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:28.206546Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT05805605","Allo HSCT Using RIC and PTCy for Hematological Diseases",[45],"2026-08-26T02:17:29.353236Z","2026-05-05T02:43:28.075410Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT06395103","Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A\u002FLIGHTBEAM-U01)",[12],"2026-08-26T02:17:43.321968Z","2026-05-05T02:43:28.012234Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT01371630","Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia",[12],"2026-08-26T02:18:52.966503Z","2026-05-05T02:43:27.961680Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT06340737","AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w\u002FRecurrent\u002FRefractory B Cell Lymphomas",[20],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:27.925479Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT04195633","Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies",[45],"2026-08-26T02:17:07.954622Z","2026-05-05T02:43:27.479357Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT06533579","Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)",[12],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.324190Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT05990465","LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies",[20],"2026-08-26T02:18:14.396999Z","2026-05-05T02:43:27.263994Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT07097363","Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma",[45],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:27.261789Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT03125642","Auto Stem Cell Transplant for Lymphoma Patients",[45],"2026-08-26T02:16:13.426928Z","2026-05-05T02:43:26.753431Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":154,"content_modified":166},"NCT05773040","A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas",[20],"2026-05-05T02:35:31.752653Z",{"nct_id":168,"title":169,"phases":170,"status":13,"updated_at":171,"content_modified":172},"NCT05327023","Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies",[12],"2026-08-26T02:16:15.345907Z","2026-05-05T02:35:31.707199Z",{"nct_id":174,"title":175,"phases":176,"status":13,"updated_at":177,"content_modified":178},"NCT06173518","A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)",[20],"2026-08-26T02:17:21.315591Z","2026-05-05T02:35:31.644184Z",{"nct_id":180,"title":181,"phases":182,"status":13,"updated_at":183,"content_modified":184},"NCT06131801","Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution",[],"2026-08-26T02:15:45.413021Z","2026-05-13T02:55:06.418667Z",{"nct_id":186,"title":187,"phases":188,"status":13,"updated_at":21,"content_modified":189},"NCT03375619","Long-term Follow-up Study of Patients Receiving CAR-T Cells",[],"2026-05-13T02:55:06.122685Z",{"nct_id":191,"title":192,"phases":193,"status":194,"updated_at":195,"content_modified":196},"NCT07662928","Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study",[45],"NOT_YET_RECRUITING","2026-08-26T02:15:01.639696Z","2026-07-05T03:45:20.354557Z",{"nct_id":198,"title":199,"phases":200,"status":194,"updated_at":201,"content_modified":202},"NCT07701889","Bispecific CD19\u002FCD20-Targeted Chimeric Antigen Receptor (CAR) Modified T Cells With 4-1BB and Mutated CD28 Costimulatory Domains in Patients With Relapsed or Refractory CD19+ Hematologic Malignancies",[20],"2026-08-26T02:19:01.741747Z","2026-07-19T19:36:05.085306Z",{"nct_id":204,"title":205,"phases":206,"status":207,"updated_at":208,"content_modified":209},"NCT07168486","CD19.20.22 CAR T-cells for Patients With Relapsed\u002FRefractory B-Cell Lymphomas",[20],"ENROLLING_BY_INVITATION","2026-08-26T02:19:19.975067Z","2026-06-16T05:54:07.870155Z",{"nct_id":211,"title":212,"phases":213,"status":214,"updated_at":215,"content_modified":216},"NCT04970901","A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)",[20],"ACTIVE_NOT_RECRUITING","2026-08-03T03:54:23.387833Z","2026-05-05T02:43:29.151595Z",{"nct_id":218,"title":219,"phases":220,"status":214,"updated_at":221,"content_modified":222},"NCT04739813","Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed\u002FRefractory B-cell Lymphoma",[20],"2026-08-03T03:23:28.660374Z","2026-05-05T02:43:28.883413Z",[224,228,232,236,239,242,245],{"biomarker":225,"count":226,"slug":227},"CD19 Gene",6,"cd19-gene",{"biomarker":229,"count":230,"slug":231},"HIV Infection",5,"hiv-infection",{"biomarker":233,"count":234,"slug":235},"BCL2 Gene",3,"bcl2-gene",{"biomarker":237,"count":234,"slug":238},"BCL6 Gene","bcl6-gene",{"biomarker":240,"count":234,"slug":241},"CD22 Gene","cd22-gene",{"biomarker":243,"count":234,"slug":244},"MS4A1 Gene","ms4a1-gene",{"biomarker":246,"count":234,"slug":247},"MYC Gene","myc-gene",[249,253,257,261,264,267,270,273,276,279,283,286,289,292,295,298],{"state":250,"count":251,"slug":252},"Texas",10,"texas",{"state":254,"count":255,"slug":256},"New York",8,"new-york",{"state":258,"count":259,"slug":260},"California",7,"california",{"state":262,"count":259,"slug":263},"Maryland","maryland",{"state":265,"count":226,"slug":266},"Florida","florida",{"state":268,"count":226,"slug":269},"Pennsylvania","pennsylvania",{"state":271,"count":226,"slug":272},"Wisconsin","wisconsin",{"state":274,"count":230,"slug":275},"Minnesota","minnesota",{"state":277,"count":230,"slug":278},"Ohio","ohio",{"state":280,"count":281,"slug":282},"Oregon",4,"oregon",{"state":284,"count":234,"slug":285},"Colorado","colorado",{"state":287,"count":234,"slug":288},"Massachusetts","massachusetts",{"state":290,"count":234,"slug":291},"North Carolina","north-carolina",{"state":293,"count":234,"slug":294},"Tennessee","tennessee",{"state":296,"count":234,"slug":297},"Utah","utah",{"state":299,"count":234,"slug":300},"Washington","washington"]